Evidence map›Paper›PMID 42780045›Full record

ArticleFrontiers in cellular and infection microbiology2026

Clinical outcomes and safety of tocilizumab in severe fever with thrombocytopenia syndrome: a retrospective multicenter cohort study.

Quanman Hu, Yehan Jin, Yaming Wei, Jundong Chen, Yan Hu, Yanyan Yang, Li Zhang, Shuaiyin Chen, Guangcai Duan

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Quanman HuCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Yehan JinCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Yaming WeiHuaiyang Disease Control and Prevention Center, Zhoukou, China.
Jundong ChenDisease Control and Prevention Center, Xinyang, China.
Yan HuDisease Control and Prevention Center, Xinyang, China.
Yanyan YangDisease Control and Prevention Center, Xinyang, China.
Li ZhangDisease Control and Prevention Center, Xinyang, China.
Shuaiyin ChenCollege of Public Health, Zhengzhou University, Zhengzhou, China.
Guangcai DuanCollege of Public Health, Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick - borne zoonotic infectious disease. Severe SFTS cases exhibit an extremely high fatality rate, but there remain no effective clinical treatments. Methods: Propensity Score Matching (PSM) and logistic regression analysis were used to assess the efficacy, safety, and baseline factors influencing patient prognosis of tocilizumab in the treatment of SFTS. Results: A total of 833 SFTS cases were included, of whom 171 received tocilizumab. After PSM, a higher recovery rate was observed in the tocilizumab group than in the control group (76.61% vs 67.70%, Conclusion: In this retrospective cohort, after PSM, tocilizumab use was associated with a higher recovery rate in SFTS patients, although the between-group difference in in-hospital mortality did not reach statistical significance. Observed differences in selected AEs were based on retrospectively recorded data and should not be interpreted as evidence of safety. Given the exploratory nature, prospective studies are warranted.

Indexed as

Antibodies, Monoclonal, HumanizedSevere Fever with Thrombocytopenia SyndromeAgedAged, 80 and overFemaleHospital MortalityHumansMaleMiddle AgedPhlebovirusPrognosisRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedtocilizumaboutcomePSMretrospectivesafetySFTStocilizumab

Identifiers

PMID42780045
PMCPMC13597313

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.